Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICX Injection in Relapsed/Refractory Multiple Myeloma
NCT07715630Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by Chongqing Precision Biotech. Primary endpoints: Maximal Tolerated Dose up to 28 days and Incidence of Adverse Events up to 28 days. Started Jul 2026; status: recruiting.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07715630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715630.